Diabetes is characterised by kidney and heart remodeling and dysfunction, largely as a result of high blood sugar. Current treatments are unable to prevent disease progression to dialysis and end-stage-organ failure. Approx 1.8 million Australians have biomedical signs of chronic kidney disease, and about half have stage 3 to 5.
Inosi Therapeutics is developing a drug targeting Insulin Regulated Aminopepetidase (IRAP). Our IRAP inhibitor drugs have demonstrated protection against diabetes-related kidney and cardiovascular disease in preclinical models and the ability to reverse fibrosis in animal models of ageing.
The company has developed a lead series with high potency and suitable drug properties, and is ready to nominate a preclinical development candidate. In this TTRA supported project, the company will progress the preclinical development candidate into IND enabling studies and Phase Ia/b clinical trial to demonstrate safety, pharmacokinetics/pharmacodynamics in healthy volunteers and a target patient population with diabetic kidney disease.
